NEW YORK (Reuters Health) - The high risk of smoking among young people with attention-deficit/hyperactivity disorder (ADHD) is not reduced by treatment with the antidepressant bupropion, according to a report in the Journal of Clinical Psychiatry. However, stimulants do seem to cut the likelihood of smoking. Bupropion is sold under the trade name Zyban when it’s prescribed to help people stop smoking, and under the name Wellbutrin when it’s prescribed to treat depression or seasonal affective disorder.
